Fresh from launching its Human Hap300 SNP chip and reporting a 55-percent gain in fourth-quarter 2005 revenues, Illumina officials last week predicted that the company will add to its product portfolio, strengthen its manufacturing capacity, build its international sales force, and ultimately achieve profitability by the end of this year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.